Ensera Launches Alliance Network to Streamline Drug-Device Combination Product Commercialisation

02 October 2026 | Friday | News

The network connects device platform and fill-finish specialists to help pharmaceutical companies coordinate manufacturing, assembly and packaging as programmes move towards commercial supply.
Image Source: Public Domain

Image Source: Public Domain

Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together leading device platform and fill-finish specialists to address the complexity of commercializing drug-device combination products.

The network currently includes injector platform providers SHL Medical, Stevanato Group and Ypsomed alongside fill-finish specialists Argonaut Manufacturing Services, and American Injectables.

Bringing a combination product to market often requires pharmaceutical companies to coordinate multiple specialist suppliers across device platforms, fill-finish, final assembly and packaging. Each handover can add complexity and slow progress, particularly when responsibilities, processes and timelines are not aligned.

The network is designed to create stronger connections between key stages of the combination product supply chain, helping pharmaceutical companies coordinate device platforms, fill-finish, final assembly and packaging, and accelerate programs towards commercial supply.

"Too many combination product programs are slowed by disconnected suppliers and difficult handovers," said Bobby O'Connor, Chief Commercial Officer at Ensera.

"The Ensera Alliance Network brings trusted specialists together around a more coordinated, responsive model, helping customers simplify commercialization, reduce risk and rapidly progress towards launch."

Darren Hieber, VP Alliance Partnerships at Ensera, said: "This network has been built on established relationships, shared experience and a practical understanding of how each organization operates.

By connecting partners across device platforms, fill-finish, final assembly and packaging, we can work more collaboratively around the needs of individual programs, identify challenges earlier and help customers navigate the transition towards commercial supply."

Ensera plans to expand the network over time, adding organizations whose capabilities, standards and approach complement those of existing members and the evolving needs of its customers.

Participation in the Ensera Alliance Network is non-exclusive. Ensera and the network participants remain independent organizations and customers may engage each company directly and separately.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close